---
id: fireqsp
name: FireQSP
website: fireqsp.com
founded: 2024
area: biosimulation
funding_stage: pre-seed
total_funding_usd_m: 0
public: false
business_model: saas
buyer:
  - pharma
  - biotech
buyer_urgency: medium
buyer_wtp: medium
sales_cycle: long
regulatory_burden: medium
tam_usd_m: 2000
data_centrality: core-moat
data_ownership:
  - public
  - generated-in-house
moat:
  - model
  - data
primary_value_chain_layer: QSP model construction tooling
input:
  - "scientific literature (papers, abstracts) across disease areas"
  - "drug-target interaction and biomarker mentions in text"
  - "mechanism-of-action and pathway descriptions"
transformation_type: generate
output:
  - "structured drug-target interactions and biomarkers extracted from papers"
  - "disease- and mechanism-organized interaction networks"
  - "exportable model scaffolds for QSP tools"
barrier_to_entry: medium
barrier_to_entry_logic: Extraction accuracy on dense pharmacology text plus a growing curated interaction corpus is a real asset, but the underlying LLM extraction stack is increasingly commoditized and incumbents can add the workflow.
hardness: hard
hardness_reason: Extracting mechanistic biology from literature accurately enough that modelers trust the output without manual re-verification of every interaction.
substrate_family: C
substrate_tags:
- C.2
- C.3
technology_platform_ids:
  - biosimulation-qsp
new_capability: "AI extraction of drug-target interactions and biomarkers from literature to auto-assemble QSP model scaffolds in minutes."
technology_readiness_level: 6
commercialisation_status: pilot_deployment
customer:
  - pharma
  - biotech
limiting_factor: "Extraction fidelity on dense pharmacology text is unproven and incumbents can bundle equivalent workflows."
last_verified: "2026-07-07"
---

## One-liner

AI platform that extracts drug-target interactions and biomarkers from scientific literature to build QSP models in minutes rather than months, positioned as the "Cursor for QSP."

## Problem

Quantitative systems pharmacology models require modelers to manually read hundreds of papers to assemble the biological interactions underpinning a model, a slow bottleneck that gates QSP adoption.

## Workaround

Manual literature review, spreadsheet interaction curation, in-house pharmacology teams, and generic QSP-Copilot-style LLM assistants.

## Entry wedge

Automated literature-to-interaction-network extraction organized by disease area and mechanism, collapsing the most labor-intensive step of QSP model building.

## Method

The platform ingests scientific papers and uses AI to extract drug-target interactions and biomarkers, organizes them by disease and mechanism of action, generates interaction networks, and exports model scaffolds for downstream QSP tools. Public metrics cite 2,000+ papers analyzed, 1M+ interactions mapped, across 20+ disease areas.

## TAM logic

The QSP and mechanistic-modeling tooling niche is a low-single-billions slice of the broader biosimulation market. Value comes from compressing modeler time on the highest-effort step; adoption scales if extraction is trusted enough to skip manual re-verification.

## Validated by

Public platform with a free trial and demo funnel; self-reported coverage of 2,000+ papers and 1M+ mapped interactions across metabolic, autoimmune, and oncology areas. No disclosed funding, named customers, or peer-reviewed validation found as of verification date.

## Competes with

Certara IQ (AI-enabled QSP), QSP-Copilot (academic multi-agent QSP platform), and internal pharma modeling groups building bespoke extraction pipelines.

## Complements

QSP and PBPK modeling tools (Certara, Simulations Plus) that consume the extracted networks, and literature databases that supply the source papers.

## Value chain position

**Downstream of:** Published scientific literature, target and pathway biology
**Upstream of:** QSP model building, mechanistic simulation, dose and trial design

## Gaps

No public funding, founding-team, or customer data, so commercial traction is unverified. Extraction fidelity on nuanced pharmacology text is the core technical risk. Incumbents (Certara IQ) can bundle equivalent extraction into existing modeling suites, compressing the wedge.

## Notes

Thin public record. Founding year (2024) is an estimate based on the platform's recency; funding stage inferred as pre-seed given absence of disclosed rounds. Positioning as "Cursor for QSP" signals an IDE-style modeler-copilot ambition rather than a full end-to-end simulation platform.

## News signals
- 2026-07: Public platform live at fireqsp.com advertising literature-to-QSP-model extraction across 20+ disease areas, 2,000+ papers, and 1M+ mapped interactions. (source: https://fireqsp.com/)
